• Login
    Browsing Dementia by Title 
    •   ORKA Home
    • Conditions, Lifestyle Factors & Interventions
    • Conditions
    • Dementia
    • Browsing Dementia by Title
    •   ORKA Home
    • Conditions, Lifestyle Factors & Interventions
    • Conditions
    • Dementia
    • Browsing Dementia by Title
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browsing Dementia by Title

    • 0-9
    • A
    • B
    • C
    • D
    • E
    • F
    • G
    • H
    • I
    • J
    • K
    • L
    • M
    • N
    • O
    • P
    • Q
    • R
    • S
    • T
    • U
    • V
    • W
    • X
    • Y
    • Z

    Sort by:

    Order:

    Results:

    Now showing items 9-28 of 31

    • title
    • issue date
    • submit date
    • xmlui.ArtifactBrowser.ConfigurableBrowse.sort_by.discipline
    • ascending
    • descending
    • 5
    • 10
    • 20
    • 40
    • 60
    • 80
    • 100
      • Thumbnail

        Early- and subsequent- response of cognitive functioning in Alzheimer's disease: Individual-participant data from five pivotal randomized clinical trials of donepezil 

        Cipriani, Andrea (2022-02)
        The association between early improvement and subsequent change in cognition is unexamined in antidementia clinical trials. We aimed to examine the consequences of early-response to antidementia medication in Alzheimer's ...
      • Thumbnail

        Effect of trazodone on cognitive decline in people with dementia: Cohort study using UK routinely collected data 

        Smith, Tanya (2021-09)
        Evidence in mouse models has found that the antidepressant trazodone may be protective against neurodegeneration. We therefore aimed to compare cognitive decline of people with dementia taking trazodone with those taking ...
      • Thumbnail

        Ethics of Early Intervention in Alzheimer’s Disease 

        External author(s) only (2021-03)
        Alzheimer’s disease (AD) research, treatment, and prevention focus increasingly on developing personalized interventions based on personal genetic, biological, phenotypic data, for early intervention (EI) to limit harm. ...
      • Thumbnail

        Evaluating the Feasibility of Frequent Cognitive Assessment Using the Mezurio Smartphone App: Observational and Interview Study in Adults With Elevated Dementia Risk 

        External author(s) only (2020-04)
        Background: By enabling frequent, sensitive, and economic remote assessment, smartphones will facilitate the detection of early cognitive decline at scale. Previous studies have sustained participant engagement with remote ...
      • Thumbnail

        Health Outcome Prioritization in Alzheimer's Disease: Understanding the Ethical Landscape. 

        External author(s) only (2020-07)
        BACKGROUND:Dementia has been described as the greatest global health challenge in the 21st century on account of longevity gains increasing its incidence, escalating health and social care pressures. These pressures highlight ...
      • Thumbnail

        Identification of Substrate-specific Allosteric Fingerprints in Matrix Metalloprotease-1 on Amyloid-beta Peptide Aggregates and Drug Screening With Single Molecule Insights 

        External author(s) only (2022-02)
        Amyloid-beta peptide (Aβ) is the primary component of water-insoluble extracellular plaques, one of the critical hallmarks of Alzheimer's disease (AD). Matrix metalloproteases (MMPs) are broad-spectrum proteases with ...
      • Thumbnail

        The impact of assistive technology on burden and psychological well-being in informal caregivers of people with dementia (ATTILA Study) 

        Howard, Robert (2020-09)
        Introduction: Assistive technology and telecare (ATT) may alleviate psychological burden in informal caregivers of people with dementia. This study assessed the impact of ATT on informal caregivers’ burden and psychological ...
      • Thumbnail

        The impact of social isolation due to the COVID-19 pandemic on patients with dementia and caregivers 

        Raymont, Vanessa; Colston, Amanda (2022-04)
        Objective: Social distancing to limit COVID-19 transmission has led to extensive lifestyle changes, including for people with dementia (PWD). The aim of this study, therefore, was to assess the impact of lockdown on the ...
      • Thumbnail

        Incidence of neurodegenerative and cerebrovascular diseases associated with antihypertensive drug classes 

        Harrison, Paul J; Colbourne, Lucy (2021-01)
        Antihypertensive drugs (AHTs) are associated with lowered risks of neurodegenerative diseases and stroke. However, the relative risks associated with different AHT classes are unclear. Using an electronic health record ...
      • Thumbnail

        Linking the Mini-Mental State Examination, the Alzheimer’s Disease Assessment Scale–Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil 

        Cipriani, Andrea (2020-10)
        Background The Mini-Mental State Examination (MMSE), the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) and the Severe Impairment Battery (SIB) are widely used rating scales to assess cognition in ...
      • Thumbnail

        Memory tests for the diagnosis of MCI: A systematic review and meta-analysis 

        Casey, Daniel; Ebmeier, Klaus P (2019-03)
        MCI is regarded as a prodrome to dementia, involving subjective memory complaint, greater forgetfulness than one would expect for age and intact activities of daily living in a patient not meeting criteria for dementia. ...
      • Thumbnail

        Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study 

        External author(s) only (2020-04)
        Background Inflammatory processes have been shown to play a role in dementia. To understand this role, we selected two anti-inflammatory drugs (methotrexate and sulfasalazine) to study their association with dementia ...
      • Thumbnail

        Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease A Randomized Clinical Trial 

        External author(s) only (2019-11)
        IMPORTANCE There are no disease-modifying treatments for Alzheimer disease (AD), the most common cause of dementia. Minocycline is anti-inflammatory, protects against the toxic effects of β-amyloid in vitro and in animal ...
      • Thumbnail

        Neurons derived from individual early Alzheimer’s disease patients reflect clinical vulnerability 

        External author(s) only (2021-11)
        Modelling sporadic Alzheimer’s disease (sAD) with patient-derived induced pluripotent stem cells (iPSCs) is challenging yet remains an important step in understanding the disease. Here we report a novel approach of sAD ...
      • Thumbnail

        Patient attitudes towards remote memory clinic assessment 

        Blane, Jasmine; O'Donoghue, M Clare; Craig, Emma; Raymont, Vanessa; Mackay, Clare; Martos, Lola (2021-12)
        Background: Due to demand on UK memory clinic services, most patients have limited consultant interaction before diagnosis/discharge. Technology offers an opportunity for remote assessment, from telephone/video-based ...
      • Thumbnail

        Personalised treatment for cognitive impairment in dementia: development and validation of an artificial intelligence model 

        Cipriani, Andrea (2022-02)
        Donepezil, galantamine, rivastigmine and memantine are potentially effective interventions for cognitive impairment in dementia, but the use of these drugs has not been personalised to individual patients yet. We examined ...
      • Thumbnail

        Quantification of allosteric communications in matrix metalloprotease-1 on alpha-synuclein aggregates and substratedependent virtual screening 

        External author(s) only (2021-01)
        Alpha-synuclein (aSyn) has implications in pathological protein aggregations observed in neurodegenerative disorders, including Parkinson's and Alzheimer's diseases. There are currently no approved prevention and cure ...
      • Thumbnail

        Quantifying the heterogeneity of cognitive functioning in Alzheimer’s disease to extend the placebo-treatment dichotomy: Latent class analysis of individual-participant data from five pivotal randomized clinical trials of donepezil 

        Cipriani, Andrea (2021-02)
        Background. The extent and profiles of heterogeneity in cognitive functioning among participants in clinical trials of antidementia medication are unknown. We aimed to quantify and identify profiles of heterogeneity of ...
      • Thumbnail

        Short-term memory advantage for brief durations in human APOE ε4 carriers 

        External author(s) only (2020-06)
        The Apolipoprotein-E (APOE) ε4 gene allele, the highest known genetic risk factor for Alzheimer’s disease, has paradoxically been well preserved in the human population. One possible explanation offered by evolutionary ...
      • Thumbnail

        Treatment for depression comorbid with dementia 

        Baruch, Nina (2019-11)
        Depression is a common comorbidity in dementia. Randomised controlled studies of antidepressants do not show a significant improvement in depressive symptoms in patients with comorbid dementia and are known to lead to an ...

        Oxford Health copyright © 2019
        Contact Us | Send Feedback | JSPUI
        Powered by KnowledgeArc
         

         

        Browse

        All of ORKACommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsContributor DisciplineThis CollectionBy Issue DateAuthorsTitlesSubjectsContributor Discipline

        My Account

        Login

        Researcher Profiles

        Researchers

        Oxford Health copyright © 2019
        Contact Us | Send Feedback | JSPUI
        Powered by KnowledgeArc